SCHEMBL7658111

SCHEMBL7658111

CCOC(CCc1nn(C)c2cc(C(=O)OC)ccc12)OCC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.37
▸ CNR2 P34972 1/20 0.36
▸ ALDH1A1 P00352 8/20 0.36
▸ HSD17B10 Q99714 4/20 0.36
▸ HPGD P15428 4/20 0.36
▸ KMT2A Q03164 4/20 0.36
▸ MEN1 O00255 3/20 0.36
▸ MAPT P10636 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ TSHR P16473 4/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ APOBEC3A P31941 1/20 0.35
▸ APOBEC3G Q9HC16 1/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ ERAP2 Q6P179 2/20 0.34
▸ LNPEP Q9UIQ6 2/20 0.34
▸ ATM Q13315 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8682731 0.86 KDM4E (0.39) KDM4EALDH1A1HSD17B10HPGDKMT2A
SCHEMBL8682285 0.83 SLC22A12 (0.44) CNR2ALDH1A1HPGDKMT2AMEN1
SCHEMBL27272748 0.82 SLC22A12 (0.44) KDM4EALDH1A1HSD17B10HPGDKMT2A
SCHEMBL28472884 0.81 TLR8 (0.41) KDM4EALDH1A1HSD17B10HPGDKMT2A
SCHEMBL7658563 0.80 ALDH1A1 (0.43) KDM4EALDH1A1HSD17B10HPGDKMT2A
SCHEMBL28468125 0.80 LOXL2 (0.46) KDM4EALDH1A1HSD17B10HPGDKMT2A
SCHEMBL7656202 0.79 KDM4E (0.38) KDM4EALDH1A1HSD17B10HPGDKMT2A
SCHEMBL7655673 0.78 LMNA (0.47) KDM4EALDH1A1HSD17B10HPGDKMT2A
SCHEMBL28019314 0.75 GRM4 (0.44) KDM4ECNR2ALDH1A1HSD17B10HPGD
SCHEMBL7665062 0.75 KDM4E (0.37) KDM4ECNR2ALDH1A1HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6489333-B2 HETEROCYCLIC COMPOUNDS CONTAINING A GUANIDINE MIMIC, FOR INHIBITION OF CELL ADHESION, TREATMENT OF ANGIOGENESIS DISORDERS, INFLAMMATION, CANCER METASTASIS, DIABETIC RETINOPATHY, THROMBOSIS, RESTENOSIS, MACULAR DEGENERATION BRISTOL - MEYERS SQUIBB PHARMA COMPANY 2002-12-03 — — US disclosed
US-20010044535-A1 Integrin antagonists BRISTOL-MYERS SQUIBB PHARMA COMPANY 2001-11-22 — — US disclosed
US-5760028-A TREATING CANCER METASTASIS, DIABETIC RETINOPATHY, NEOVASCULAR GLAUCOMA, THROMBOSIS, RESTENOSIS, OSTEOPOROSIS, MACULAR DEGENERATION THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1998-06-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010044535-A1 Integrin antagonists ITGB3, VCAM1, ITGB2 KDM4E 3935/4885CNR2 1105/4885ALDH1A1 2216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback